Beta-interferons in multiple sclerosis
نویسندگان
چکیده
منابع مشابه
Interferons in relapsing remitting multiple sclerosis.
BACKGROUND Recombinant interferons have been shown to suppress both the clinical and magnetic resonance imaging (MRI) measures of disease activity in patients with relapsing remitting multiple sclerosis (RRMS). OBJECTIVES We performed a Cochrane review of all randomised, placebo-controlled trials of recombinant interferons in RRMS. SEARCH STRATEGY Of 208 articles identified by a predefined ...
متن کاملInterferons and Natalizumab for Multiple Sclerosis
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system which is accompanied by considerable disability and high costs. This report summarises the evidence on effectiveness and costs of beta-interferons and natalizumab in the treatment of multiple sclerosis.The review included systematic reviews and randomised controlled trials (with an observation time of at lea...
متن کاملApproved Beta Interferons in Relapsing-Remitting Multiple Sclerosis: Is There an Odd One Out?
Three interferons are marketed for the treatment of relapsing-remitting multiple sclerosis. In its pivotal trial, one of them demonstrated impressive efficacy as a once-weekly regimen, but later head-to-head studies and reviews questioned its superiority. Analysis of this pivotal trial in publications and health authority reviews has shown that its early termination might have caused attrition ...
متن کاملGuideline for the use of beta-interferons in patients with multiple sclerosis--a South African proposal.
AIM To determine guidelines for use of beta-interferons in South African patients with multiple sclerosis. METHOD Review of existing international protocols. Opinions of South African neurologists who have an interest in multiple sclerosis. CONCLUSIONS The main indication for interferon use is the relapsing and remitting form of multiple sclerosis.
متن کاملAzathioprine versus Beta Interferons for Relapsing-Remitting Multiple Sclerosis: A Multicentre Randomized Non-Inferiority Trial
UNLABELLED For almost three decades in many countries azathioprine has been used to treat relapsing-remitting multiple sclerosis. However its efficacy was usually considered marginal and following approval of β interferons for this indication it was no longer recommended as first line treatment, even if presently no conclusive direct β interferon-azathioprine comparison exists. To compare azath...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Indian Academy of Neurology
سال: 2010
ISSN: 0972-2327
DOI: 10.4103/0972-2327.74189